The precision medication Datroway, developed by AstraZeneca and its partner Daiichi Sankyo, has been approved by US regulators to treat a particular kind of lung cancer. This is the first time the therapy has been approved for this indication, and it will increase patient access.
AstraZeneca announced on Tuesday that Datroway, the first therapy of its kind to receive approval in the United States, the largest pharmaceutical market in the world, has been approved to treat an advanced form of non-small cell lung cancer in adults who have already received treatment.
Datroway is a member of the class of medications known as antibody-drug conjugates, or “guided-missiles” since, in contrast to traditional chemotherapy, it is made to target only cancer cells while leaving healthy cells unharmed.
